Skip to main content

Table 2 Studies included in each network meta-analysis

From: Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups

StudiesAll licensed doses (N = 69)Patients with no previous biologic use (< 25% had previous use)
(N = 34)
Patients with PASI score ≤ 25 (N = 59)Patients with weight ≤ 90 kg (N = 28)White patients (≥ 90% white) (N = 42)
AMAGINE1 2016  
AMAGINE2 2015  
AMAGINE3 2015
Nakagawa 2016  
Papp 2012  
CHAMPION 2008 
Goldminz 2015   
Cai 2016  
REVEAL 2008 
Asahina 2010   
Gordon 2006  
XPLORE 2015  
Bissonnette 2013  
VOYAGE1 2017  
VOYAGE2 2017  
PSOR005 2012  
ESTEEM1 2015  
ESTEEM2 2015  
Ohtsuki 2017 
LIBERATE 2016
Leonardi 2003   
Gottlieb 2003  
Papp 2005  
VandeKerkhof 2008 
Bagel 2012  
Bachelez 2015 
Tyring 2006   
PRISTINE 2013 
M10114 2011 
M10315 2011 
reSURFACE2
PIECE 2016 
Yang 2012  
EXPRESS 2005  
Chaudhari 2001
SPIRIT 2004  
EXPRESSII 2007 
Torii 2010   
RESTORE1 2011
UNCOVER1 2016  
UNCOVER2 2015 
UNCOVER3 2015 
IXORAS 2017
FEATURE 2015  
ERASURE 2014  
FIXTURE 2014 
JUNCTURE 2015 
CLEAR 2015 
PEARL 2011 
PHOENIX1 2008  
PHOENIX2 2008  
LOTUS 2013 
ACCEPT 2010 
Igarashi 2012  
BRIDGE 2017 
Caproni 2009  
Gisondi 2008  
Meffert   
PappD 2015   
ReSURFACE1 
ultIMMA1    
ultIMMA2    
METOP 
Krueger   
Reich 2012
CIMPACT 2018 
CIMPASI1 2018  
CIMPASI2 2018  
UNVEIL